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Previous studies demonstrated that chronic dermal exposure to the pesticide adjuvant (surfactant), Toximul™ (Tox), has significant detrimental
effects on hepatic lipid metabolism. This study demonstrated that young mice dermally exposed to Tox for 12 days have significant increases in
expression of peroxisomal acyl-CoA oxidase (mRNA and protein), bifunctional enzyme (mRNA) and thiolase (mRNA), as well as the P450
oxidizing enzymes Cyp4A10 and Cyp4A14 (mRNA and protein). Tox produced a similar pattern of increases in wild type adult female mice but
did not induce these responses in PPARα-null mice. These data support the hypothesis that Tox, a heterogeneous blend of nonionic and anionic
surfactants, modulates hepatic metabolism at least in part through activation of PPARα. Notably, all three groups of Tox-treated mice had
increased relative liver weights due to significant accumulation of lipid. This could be endogenous in nature and/or a component(s) of Tox or a
metabolite thereof. The ability of Tox and other hydrocarbon pollutants to induce fatty liver despite being PPARα agonists indicates a novel
consequence of exposure to this class of chemicals, and may provide a new understanding of fatty liver in populations with industrial exposure.
© 2007 Elsevier B.V. All rights reserved.Keywords: Pesticide adjuvant; PPARα; PPARα-null mice; MRNA and protein expression; Cyp4A; Peroxisomal fatty-acid oxidation1. Introduction
Millions of tons of industrial surfactants (IS) are used annually
by the textile, paint, cleaning supplies and agricultural/forestry
industries, and use is increasing [1]. The agricultural/forestry
industries rely on IS as adjuvants to emulsify water-insoluble
pesticides to optimize the spreading, retention and uptake of
active ingredients. These adjuvants can constitute up to 90% ofAbbreviations: IS, industrial surfactant(s); Tox, Toximul; pFAO, peroxiso-
mal fatty-acid β-oxidation; mFAO, mitochondrial FAO; qPCR, quantitative
polymerase chain reaction; PPARα, peroxisome proliferator-activated receptor
alpha; PPARα(−/−), PPARα-null mice; PPARα(+/+), PPARα wild type mice;
ACOX, acyl-CoA oxidase; L-PBE, peroxisomal bifunctional enzyme; pTHIO,
peroxisomal 3-ketoacyl-CoA thiolase; Cyp4A, cytochrome P4504A; CTRL,
control (no Tox exposure)
⁎ Corresponding author. Fax: +1 902 494 1685.
E-mail address: mary.murphy@dal.ca (M.G. Murphy).
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doi:10.1016/j.bbadis.2007.06.003pesticide formulations [2]. However, since they are considered by
industry as ‘inert ingredients’, their use is largely unregulated and
information regarding their composition is rarely available. Many
of the Toximul™ (Tox) class of adjuvants are blends of
structurally heterogeneous nonionic and anionic hydrocarbons
(e.g., polyethylene glycol ethers, alkyl benzene sulfonates). The
nonionic components are partially degraded to more toxic
environmentally persistent metabolites, some of which (e.g.,
nonylphenol) are known endocrine disrupting chemicals [3].
A far less known consequence of environmental contaminant
exposure is disruption of hepatic energy metabolism. During the
past decade we have investigated the effects of Tox exposure on
fat and carbohydrate metabolism in neonatal mouse livers as part
of our long-term study of Tox potentiation of influenza B-
induced mortality [2,4]. Mice exposed dermally to Tox daily for
12 consecutive days exhibit significant stimulation of perox-
isomal fatty-acid β-oxidation (FAO) [5] and inhibition of
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tines [7] and significant reductions in glycogen content [2]. In
spite of these metabolic disturbances, the young mice have no
apparent adverse health effects from Tox exposure.
Our previous efforts to elucidate the mechanism(s) under-
lying these metabolic derangements have been unsuccessful.
However, a unifying mechanism has been described for the
regulation of hepatic lipid homeostasis by many structurally
diverse xenobiotic hydrocarbons (clofibrates, phthalates, pesti-
cides) as well as endogenous metabolites (e.g., fatty acids, pro-
staglandins) [8]. Peroxisome proliferator-activated receptor
alpha (PPARα) is a member of the superfamily of ligand-
activated nuclear transcription regulators. When activated,
PPARα is the ‘master switch’ that controls transcription of a
host of genes involved in energy metabolism. The primary
structural requirements for ligands of PPARα appear to be
lipophilicity and a carboxyl functional group [9]. Recent in vitro
studies demonstrated that perfluorooctane based chemicals,
powerful IS used primarily in the paper and textile industries,
can activate downstream targets of both human and mouse
PPARα [10]. However no one has examined the effects of
adjuvants commonly used in pesticide formulations, even
though it is known that these chemicals can be more toxic than
the active ingredients [11].
The purpose of this study was to determine whether chronic
dermal exposure of young mice to Tox results in altered hepatic
expression of PPARα and/or its target enzymes involved in lipid
metabolism. To assess PPARα involvement in the Tox re-
sponses, we also determined the effects of the surfactant in adult
PPARα-null mice (PPARα(−/−)) and their corresponding wild
type (PPARα(+/+)) controls.
2. Materials and methods
2.1. Neonatal mice
Male and female CD-1(ICR) outbred mice (Charles River, St. Constant,
QU, Canada) were bred and newborn pups were pooled on postnatal day (P)
one and divided randomly among nursing mothers. Twenty-four hours later,Table 1
qPCR primers
Gene GenBank accession numb
aACOX—acyl-Coenzyme A oxidase 1 NM_015729
dCyp4a10—cytochrome P450 4A10 NM_010011
aCyp4a14—cytochrome P450 4A14 NM_007822
aL-PBE—L-specific peroxisomal bifunctional
enzyme (Ehhadh)
NM_023737
aRPII—RNA polymerase II largest subunit U37500
dpTHIO—peroxisomal 3-ketoacyl-CoA thiolase
A and B (Acaa1a, Acaa1b)
NM_130864
NM_146230
a Purchased from Invitrogen Corporation.
b Fw, forward primer.
c Rv, reverse primer.
d Purchased from Sigma-Aldrich Canada Ltd.the litters were divided into two equal groups. In the control group (CTRL),
minimal essential medium (MEM) was applied dermally to the abdomens of
the pups. The remainder were painted with Tox 3409F (Stepan Company,
Northfield IL) diluted in MEM (1:8, vol:vol)(∼1 mg Tox/g/day). These treat-
ments were repeated daily for 12 days (P2–P13). Body weights were recorded
daily. On P13 the mice were killed by decapitation and the livers were excised,
weighed and flash frozen for storage at −80 °C until assessed. In this study only
female CD-1 mice were used, although preliminary experiments indicated that
Tox-induced changes in mRNA expression were not gender specific in the pups
on P13.
2.2. PPARα(+/+) and PPARα(−/−) mice
Age-matched (14–18 weeks) wild type (C57BL/6, PPARα(+/+)) female
mice (22±1.3 g) and PPARα(−/−) mice (22.2±1.2 g) originated from the
laboratory of Lee et al. [12] and were a gift to C. Sinal from Dr. F. Gonzalez,
National Cancer Institute, National Institutes of Health, Bethesda, MD. Half of
each group had Tox applied on their abdomens daily for 12 days at doses
equivalent (wt/wt) to those to which the neonates were exposed. The remainder
of each group received MEM. The mice were fed standard rodent diet ad libitum
throughout the experiment. Body weights were recorded daily. After 12 days
painting the mice were killed and their livers weighed and treated as described
above. All mouse studies were carried out in compliance with the guidelines of
the Canadian Council on Animal Care and approved by Dalhousie University's
Committee on Laboratory Animals.
2.3. Quantitative PCR (qPCR) analysis
Total RNAwas isolated from frozen livers using TRIzol reagent (Invitrogen
Corporation, Burlington, Canada) and reverse-transcribed using a QuantiTect
Reverse Transcription kit (Qiagen Inc., Mississauga, Canada) according to the
manufacturer's instructions. cDNA products (2 μL) were amplified by qPCR
using gene-specific primers (0.5 μM) and the QuantiTect SYBR Green PCR kit
(Qiagen) in a total volume of 20 μL using a LightCycler 2.0 thermocycler
(Roche Diagnostics, Laval, Canada). The primers used and their sources are
shown in Table 1. Amplification consisted of a 15-min hot start (95 °C)
followed by 35 cycles of denaturation (94 °C, 15 s), annealing (60 °C, 30 s) and
elongation (72 °C, 30 s). Melting curves followed by separation of PCR
products on a 2.5%, 0.5× TAE agarose gel were done to ensure the formation of
a single product at the appropriate size. Relative gene expression, normalized to
the reference gene RNA polymerase II (RPII), was calculated using the −2ΔΔCT
method [13]. RPII was used as the housekeeping gene as its expression is
constant throughout development, is not gender specific and is not influenced
by Tox exposure (not shown). To demonstrate the relative abundance of
mRNAs, data for both CTRL and Tox-treated mice were expressed relativeer PCR primer sequences (5′ to 3′) PCR product size (bp)
Fw b: accgcctatgccttccactttc 180
Rv c: gcaagccatccgacattcttcg
Fw: ttccctgatggacgctcttta 116
Rv: gcaaacctggaagggtcaaac
Fw: gtctctcggggcaatatcg 119
Rv: accaatccagggagcaaagaa
Fw: aaagctagtttggaccatacgg
Rv: atgtaaggccagtgggagatt
109
Fw: ctggacctaccggcatgttc 132
Rv: gtcatcccgctcccaacac
Fw: gactgtacctttgtctacggtca
Rv: tgccaatgtcataagacccattt
101
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PPARα(+/+), PPARα(−/−)).
2.4. Immunoblot analysis
For most Western blot analyses, frozen liver samples (∼0.1 g) were
homogenized in 0.5 mL of ice cold buffer containing 20 mM Tris–HCl (pH 7.4),
0.25 M sucrose, 1 mM EDTA, 25 mM KCl, 1 mM dithiothreitol and a complete
protease inhibitor cocktail (Roche Diagnostics). Triton X-100 (1%, v/v) was
added and after 30 min incubation on ice, the homogenates were centrifuged
(3000×g, 10 min, 4 °C) and supernatants collected. For PPARα analysis, nuclear
extracts were prepared essentially as described by Gebel et al. [14]. Briefly,
∼0.1 g of liver were homogenized in 0.3 mL of buffer (above), the nuclei were
pelleted and resuspended in fresh buffer containing 0.4 M NaCl. The
suspensions were mixed (4 °C, 30 min) and centrifuged (2000×g, 4 °C,
30 min), and supernatants (nuclear extracts) were collected. Protein was
analyzed using a kit from Bio-Rad Laboratories (Mississauga, Canada) with
bovine serum albumin as standard.
Liver homogenates or nuclear extracts (15 μg protein) were separated on 10%
SDS-polyacrylamide gels, transferred to PVDF membranes and the membranes
were blocked in TBST buffer (20 mM Tris–HCl [pH 7.5], 55 mM NaCl, 0.1%
Tween 20) containing 5% non-fat milk powder and incubated with primary
antibody for 1–2 h. Primary antibodies and dilutions used were as follows: goat
anti-β-actin (1:500, Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-
murine PPARα (1:1000, Santa Cruz), rabbit anti-rat CYP4A (1:3000, Affinity
BioReagents, Golden, CO), rabbit anti-rat ACOX 1 [15], and rabbit anti-rat
pTHIO [16]. The last two were generous gifts from Dr. P.P. Van Veldhoven, K.U.
Leuven, Belgium, and were used at 1:4000 dilutions. An antibody to L-PBE is
not commercially available, which precluded analysis of this protein. TBSTwas
used as wash buffer and antibody diluent. After washing 5×5 min, blots were
incubated (45 min) with horseradish peroxidase-conjugated secondary anti-
bodies, either anti-rabbit IgG (1:100,000, Chemicon, Temecula, CA) or anti-goat
IgG (1:8000, Santa Cruz). Blots were given final washes (5×10 min) and
antibody binding was detected on X-ray film by enhanced chemiluminescence
(ECL Plus, Amersham Pharmacia Biotech, Buckinghamshire, UK). The relative
intensities were quantified using NIH Image software after films were scanned
using Umax MagicScan32 software. Relative levels of protein in each group of
mice are expressed relative to P13 CTRL=1. Data for the Tox-treated mice are
expressed relative to the CTRL for its corresponding group.
2.5. Lauric acid hydroxylation assay
Cytochrome P450 ω-hydroxylase (Cyp4A) activity was determined using
liver homogenates (1 mg protein) incubated (37 °C, 10 min) in 50 mM Tris–
HCl, pH 7.4, containing 50 μM [1-14C]lauric acid (11,000 dpm/nmol,
Amersham Biosciences) and 1 mM NAPDH, in a final volume of 0.5 mL.
Blank tubes contained all reactants except NAPDH. Reactions were terminated
by addition of 0.5 mL acetonitrile and 200 mg of each of lauric and 12-
hydroxylauric acids. The mixtures were extracted with diethyl ether and organic
phases were pooled and dried under nitrogen. The residues were suspended in
25 μL methanol and reaction products were separated on silica gel on polyester
plates (Sigma-Aldrich Canada Ltd., Oakville Canada) using the solvent system
diethyl ether:petroleum ether:formic acid (70:30:1, vol:vol). Bands correspond-
ing to lauric and 12-hydroxylauric acids were cut and radioactivity was
quantitated using a scintillation counter. The data were expressed as nmol lauric
acid hydroxylated/min/mg protein.
2.6. Pathology assessment
Thin (5 μm) sections were cut from mouse livers that were either fixed in
formalin (10%, by vol) and embedded in paraffin, or flash frozen at the time of
harvest. The paraffin sections were stained with hematoxylin and eosin, and the
frozen sections were stained with Oil Red O. The sections were cut and stained
in the Clinical Chemistry Laboratory of the IWK Health Centre. To evaluate
liver fat content, images of the oil red O stained sections were analyzed using
Adobe Photoshop CS2 after all non red stained portions were converted to
white. The images were converted to grayscale, optimized for contrast, and thenumber of pixels derived from the red areas were counted (Image J, public
domain software from the National Institutes of Health) and expressed as percent
total pixel count.
2.7. Statistical analysis
The mRNA data for each set of animals are expressed relative to values for
RPII (=1) for that set. Control protein levels for the PPARα(+/+) and PPARα(−/−)
mice are expressed relative to those of the CD-1 controls (=1), and values for the
Tox-treated mice are expressed relative to the corresponding controls. Unless
indicated otherwise, data are the means±SEM of values from 4 to 12 mice.
Statistical analyses were done using the two-tailed unpaired Student's t test.3. Results and discussion
The long-term health effects of prolonged exposure to
environmental pollutants, particularly xenobiotic hydrocarbons,
is becoming of increasing concern to health care workers as well
as the general public. Atypical hydrocarbons that accumulate in
the environment or are present in human foods (e.g., phthalates,
nonylphenol, perfluorooctanoate, oxidized frying fats) are
known to alter hepatic lipid metabolism [9,17,18]. Only
recently have several in vivo studies linked these alterations
to effects on gene expression [9,19,20]. The objective of this
study was to determine whether the widespread metabolic
abnormalities that occur in young mice exposed to the pesticide
adjuvant, Tox, were due to altered function of the transcription
regulator, PPARα, and expression of its target genes involved
in pFAO.
3.1. Tox effects on expression of pFAO enzymes
In vivo, activation of PPARα by clofibrate and Wy-16,643
increased expression of all three enzymes of the pFAO pathway
(i.e., ACOX, L-PBE, pTHIO) [12]. Likewise, exposing the
CD-1 mice to Tox increased expression of mRNAs coding for
ACOX, L-PBE and pTHIO (2-, 4- and 1.7-fold, respectively)
(Fig. 1A). ACOX protein levels were also elevated (1.6-fold)
with Tox treatment, however those of pTHIO were not (Fig. 1B).
The reason for the lack of change in pTHIO protein is unclear;
perhaps it reflects an adaptive down-regulation of translation
and/or rapid protein turnover. Livers of the adult PPARα(+/+)
females exposed to Tox exhibited a similar pattern of change in
pFAO enzyme expression, with significant increases in ACOX
(mRNA and protein) and L-PBE mRNA. Levels of pTHIO
mRNA also increased, however values did not reach statistical
significance. This is consistent with the reported relative
insensitivity of adult female mice to ligand-induced increases
in pTHIO [21]. The fact that pTHIO protein was increased
(∼1.6-fold) in Tox-treated PPARα(+/+) mice may reflect a
stable protein with a long half-life (Fig. 1B). Collectively, these
data showing Tox-induced increases in expression of pFAO
enzymes (protein and/or mRNA) in CD-1 pups and PPARα(+/+)
mice are consistent with Tox effects being mediated by PPARα.
If Tox-mediated increases in pFAO activity [5] and enzyme
expression are totally dependent on PPARα, these responses
should not occur in PPARα(−/−) mice. As illustrated in Fig. 1, this
was true of ACOX mRNA and protein expression. However,
Fig. 1. Effect of Tox on expression of PPARα and peroxisomal fatty-acid β-oxidation enzymes. (A) mRNA expression Total RNAwas extracted from mouse livers,
reverse transcribed and analyzed by qPCR for expression of ACOX, L-PBE and pTHIO as described in Materials and methods. The data for each enzyme in each
mouse group (CD-1, PPARα(+/+), PPARα(−/−)) are expressed relative to mean RPII levels in that group (RPII=1). (B) Protein expression Levels of PPARα, ACOX
and pTHIO protein were quantitated by Western blot analysis as described in Materials and methods. Raw data were standardized to β-actin and all values were
standardized to those for the control CD-1 pups (CTRL=1). Values represent the mean±SEM (nS=4–12 [CD-1, PPARα(+/+)]; n=2 for PPARα(−/−) [PPARα,
Cyp4A only]). ⁎pb0.05–b0.0001, relative to values for corresponding CTRL in that group of mice. ND, not detected.
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pTHIO mRNA and protein content increased almost 3-fold. This
is one of few reports of a putative PPARα agonist increasing
expression of L-PBE in PPARα(−/−) mice [22]. It should be
emphasized that Tox-mediated increases in transcription may not
translate into increases in protein that have tangible effects on
metabolism. For example, pTHIO protein levels in the control
PPARα(−/−) mice were b10% of their PPARα(+/+) counterparts
and although these levels increased with Tox exposure they did
not exceed∼25% of the control PPARα(+/+) levels. Increases in
pTHIO expression also occurred in PPARα(−/−) mice treated
with clofibrate [12] or the branched-chain fatty-acid precursor,
phytol [22]. These findings led the authors to conclude that theseagonists can mediate responses by both PPARα-dependent and
independent pathways. Gloerich et al. [22] did not speculate on
the identity of the nuclear receptor(s) that mediate(s) PPARα-
independent effects of phytol, but two potential candidates are
liver X receptor α (LXRα) [23,24] and PPARγ [25]. The LXRα
agonist, T0901317, upregulates all three pFAO enzymes in
PPARα(−/−) mice. The natural ligands of LXRα are cholesterol
and its derivatives, however other phenolic hydrocarbons are
also potent agonists [26], and Toxmay contain structurally similar
molecules. The second candidate, PPARγ, is not highly expressed
in PPARα(+/+) mouse liver, however feeding PPARα(−/−) mice
high fat diets increased its expression by ∼4-fold [25], with a
concomitant upregulation of pFAO enzyme expression.
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Western blot analysis of the P13 mouse livers showed that
chronic dermal Tox exposure did not alter PPARα protein levels,
a finding also observed in PPARα(+/+) mice (Fig. 1B, left
panel). Predictably, PPARα protein was not detected in any
PPARα(−/−) mice (Fig. 1B, left panel). The lack of change in
PPARα protein in the pups and PPARα(+/+) mice was not
unexpected, as others also have found its levels unchanged
following exposure to PPARα agonists [9,12]. This may reflect
its demonstrated rapid turnover rate and the fact that the ability of
ligands to stabilize its expression is transitory [27].Fig. 2. Effect of Tox on hepatic Cyp4A expression and enzyme activity. (A) mRNA
Cyp4A 10 and 14; values were expressed relative to RPII values for the control group
in Fig. 1, using an antibody nonspecific for Cyp4A isoform. Data are expressed as des
livers from CD-1 pups and PPARα(+/+) mice probed for total Cyp4A protein. (C) Lau
mice as described in Materials and methods. The data are expressed as nmol lauric a
data significance are as described in Fig. 1.3.3. Tox effects on Cyp4A expression and activity
A hallmark response to activation of several nuclear
receptors, including PPARα, by xenobiotic agents is an increase
in expression of the P450 ω-hydroxylases, including Cyp4A
[28]. In all three groups of mice in our study, mRNA levels of
only two isoforms of Cyp4A (Cyp4A10 and Cyp4A14) were
sufficiently abundant to reliably detect Tox-related changes.
Characteristic of most strains of adult female mice [29],
expression of Cyp4A12 was extremely low (≤0.2%) in both
the pups and adults. Cyp4A10 and 14 are the isoforms highly
inducible by PPARα ligands [12,25,30,31]. In this study, CD-1expression. Methods were as described in the legend to Fig. 1, using primers for
of corresponding mice. (B) Cyp4A protein content was quantitated as described
cribed in Fig. 1B. The insert shows representative blots of CTRL and Tox-treated
ric acidω-hydroxylase activity was measured in livers of CD-1 and PPARα(+/+)
cid ω-hydroxylated/min/mg protein (mean±SEM, n=3). Statistical analysis and
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mRNA coding for both Cyp4A10 and 14 (Fig. 2A); total
Cyp4A protein content (Fig. 2B) and enzyme activity (Fig. 2C)
were also increased (∼6- and N3-fold, respectively). It should
be noted that the Cyp4A antibody does not distinguish between
isoforms. Consistent with earlier reports [30], there were no
gender-specific differences in the responses of the P13 pups to
Tox (not shown). PPARα(+/+) adult females treated with Tox
also had increased levels of Cyp4A14 mRNA, total Cyp4A
protein and enzyme activity (4-, 5- and N6-fold, respectively)
(Fig. 2). Cyp4A10 mRNA was increased, however values did
not reach statistical significance. One possible explanation is
that upregulation of this isoform does not occur except with
very long exposure, as seen with dioxin treatment [28].
PPARα(−/−) mice had predictably low constitutive levels of
Cyp4A10 and 14, and no change in Cyp4A14 mRNA occurred
with Tox exposure (Fig. 2A). Unexpectedly, Cyp4A10 content
was increased ∼4-fold with Tox treatment. However, Anderson
et al. recently determined that Cyp4A10 was the one Cyp4A
isoform whose expression was regulated independent of
PPARα [24]. They provided evidence that this could occur by
binding of the ligand (e.g., a component of Tox) to one of the
retinoid X receptors that are the mandatory heterodimeric
partners for activation of most nuclear receptors, including
PPARα, LXR and PPARγ.
3.4. Effects of Tox on liver weights and pathology
Chronic dermal exposure to Tox did not have obvious adverse
health effects on any of the mice, nor were body weights affected
(Table 2). Relative liver weights were significantly increased in
Tox treated CD-1 and PPARα(+/+) mice (12% and 37%,
respectively) (Table 2), a response typically seen in wild type
rodents exposed to the prototype PPARα agonists, clofibrate and
Wy-16,643 [12]. This effect of the latter drugs is commonly
attributed to their ability to increase hepatocyte number and/or
size, and does not occur in PPARα(−/−) mice. In contrast, relative
liver weights in Tox-treated PPARα(−/−) mice were elevated
significantly (Table 2). Pathologic assessment of stained sections
of livers from each group of mice showed vacuoles in the
PPARα(+/+) mice, a feature more prominent in the PPARα(−/−)
animals. There were no obvious structural abnormalities in the
CD-1 mice, and there was no evidence of inflammation or
increased numbers of mitotic figures in any Tox-treatedmice. The
possibility that the vacuoles were due to glycogen storage wasTable 2
Effects of 12 days of dermal exposure to Tox 3409F on body and liver weights and
Mice Treatment Body weight (g) Absolute l
CD-1 (13-day-old) Control (n=9) 6.48±0.24 0.188±0.0
Toximul 3409 (n=9) 7.01±0.15 0.227±0.0
PPARα+/+(adult) Control (n=5) 21.58±0.76 0.825±0.0
Toximul 3409 (n=5) 23.02±0.68 1.210±0.0
PPARα−/− (adult) Control (=4) 21.92±0.78 0.878±0.0
Toximul 3409 (n=4) 22.12±0.37 1.228±0.0
Values are expressed as mean±SEM. Data were analyzed by the unpaired Student's
their respective controls. ⁎pb0.05; ⁎⁎pb0.001; ⁎⁎⁎pb0.0001.ruled out as several sections stained with periodic acid schiff were
negative which indicates that the vacuoles did not contain
glycogen (data not shown). This was consistent with our earlier
findings that Tox exposure significantly reduces hepatic glycogen
[2]. Oil red O staining showed that vacuoles in the Tox-treated
livers were positive for fat (Table 2) in PPARα(−/−) and
PPARα(+/+), indicating lipid accumulation that could be
endogenous fat and/or Tox components. The absence of a
statistical difference in oil redO staining of Tox exposed P13mice
may reflect insensitivity of this assay at lower levels of
quantification, as focal areas of staining were present. There
was correlation between increases of relative liver weight and
percentage oil red O staining (Fig. 3), which supports Tox related
liver weight increases are predominantly lipid accumulation. The
finding that exposure to petroleum-derived hydrocarbons
increases relative liver weights in both PPARα(+/+) and
PPARα(−/−) mice is not unique, as Yang et al. reported the
same result in PPARα(−/−) mice fed perfluorooctanoic acid for 7
days [32]. These authors concluded that the effect on relative liver
weights was independent of PPARα. A more likely explanation
for the discrepancy between the effects of clofibrates and Tox on
relative liver weights in PPARα(−/−) mice is the marked
difference in the substrates being catabolized. Treatment with
clofibrate stimulates oxidation of endogenous fatty acids,
primarily to ketone bodies that are rapidly cleared from the
liver. By contrast, Tox is a complex mixture of linear and
branched-chain hydrocarbons, some of which likely have cyclic
and/or substituted (e.g., sulfated, methylated) components. As
with naturally occurring fatty acids, xenobiotic hydrocarbons that
reach the liver have the potential to undergo structural modifica-
tions, as well as be oxidized and/or incorporated into triglyceride
for export to the periphery [33]. There is strong evidence that
xenobiotics with abnormal structures are not completely
catabolized and fail to be esterified to form triacylglycerols,
with resultant hepatic accumulation. We observed this earlier in
livers of Tox-treated mice [34]. We propose that in both
PPARα(+/+) and PPARα(−/−) mice, the Tox components that
get into the bloodstream, either via transdermal transport or by
ingestion during grooming, are transported to the liver. Their
presence in the PPARα(+/+) mice would activate PPARα, as this
is a primary route for at least partial degradation and clearance of
xenobiotic hydrocarbons. This pathway is inactive in the
PPARα(−/−) mice, with the result that Tox components
accumulate in even higher quantities. The fact that fatty liver
also occurred, albeit to a lesser extent, in the CD-1 pups is likelyon Oil red O staining for fat
iver weight (g) Relative liver weight (%) Oil Red O % positive stain
10 2.90±0.09 0.00±0.00
05⁎ 3.24±0.04⁎ 0.00±0.00
38 3.84±0.23 0.61±0.33
27⁎⁎⁎ 5.26±0.09⁎⁎ 4.05±1.51⁎⁎⁎
31 4.00±0.04 1.60±0.38
30⁎⁎ 5.56±0.14⁎⁎⁎ 9.10±2.91⁎⁎⁎
t test for significant differences between the Toximul 3409F-treated groups and
Fig. 3.
1063J. Upham et al. / Biochimica et Biophysica Acta 1772 (2007) 1057–1064due to age- or strain-dependent differences in the pharmacokinetic
properties of the Tox components, a phenomenon observed by
others [35]. Of particular interest to this study, several groups have
reported that unmetabolized xenobiotic hydrocarbons are more
potent in activating PPARα than are endogenous ligands [36,37].
3.5. Relevance
Pesticides are ubiquitous in the environment, and concern
that exposure can pose adverse health risks is growing,
particularly as these xenobiotics are stored and accumulate for
a very long time in humans [38]. Very few active pesticide
ingredients appear to exert health risks in vivo by activation of
PPARα [31]. The ‘other’ ingredients in pesticide formulations,
the xenobiotic hydrocarbons, are often more toxic than the
active ingredients [11], yet have received very little attention.
This is the first study to obtain evidence that subclinical
dyslipidemia in young mice dermally exposed to a pesticide
adjuvant involves upregulation of select lipid metabolizing
enzymes. These effects occur despite several factors that could
attenuate the effective dose. Since Tox is a complex mixture of
structurally heterogeneous components, some components may
not penetrate skin, and those that do likely have variable
metabolic fates and liver clearance. As well, only select
components or metabolites of Tox may be responsible for
the changes in gene expression. From our data with the
PPARα(−/−) mice it appears that Tox components may serve as
ligands for more than one nuclear receptor. Whether effects on
enzyme expression are mediated through direct or indirect
activation of a nuclear receptor(s) remains to be determined.
Nevertheless, our results suggest that exposing high-risk
populations, particularly those in the petrochemical and
agricultural industries, to this class of persistent organic
chemicals has the potential to predispose them to significant
perturbations in energy metabolism and development of fatty
liver. We believe that this study has far broader implications
than exposure to pesticides, as similar effects are elicited by thewide range of structurally diverse industrial chemicals to which
humans have been exposed since the onset of industrialization.
In summary, this study has demonstrated that chronic dermal
exposure to the currently used pesticide adjuvant, Tox,
significantly increases expression of select lipid metabolizing
enzymes in livers of young and adult mice. The changes in
expression most likely to result in meaningful effects on hydro-
carbon β-oxidation (e.g., ACOX) or ω-oxidation (Cyp4A) did
not occur in PPARα(−/−) mice, suggesting involvement of
PPARα. A significant consequence of Tox exposure that
occurred despite the absence of PPARα was increased relative
liver weights and development of fatty liver (Fig. 3). Evidence
suggests that other xenobiotic hydrocarbons (e.g., perfluor-
ooctanoic acid) elicit a similar effect [32]. This is a very
important distinction between effects of the classic PPARα
agonists and environmental pollutants, and the reason we
should be even more fearful of these chemicals.
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